Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atypical antipsychotics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Atypical antipsychotics. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-004062-41 Sponsor Protocol Number: D2PET-2007 Start Date*: 2007-08-13
    Sponsor Name:Jarmo Hietala
    Full Title: Effect differences of conventional and newer atypical antipsychotics – Perphenazine and brain dopamine D2 receptor blockade
    Medical condition: Tutkittavat ovat terveitä.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011097-15 Sponsor Protocol Number: OLA_ZIPRA Start Date*: 2009-08-25
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study.
    Medical condition: The study will be conducted in 42 healthy volunteers
    Disease:
    Population Age: Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011343-39 Sponsor Protocol Number: RIS-SCH-4226 Start Date*: 2009-06-15
    Sponsor Name:Janssen-Cilag AB
    Full Title: Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders
    Medical condition: Schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder patients demanding long term antipsychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037253 Psychotic disorder NOS LLT
    9.1 10061920 Psychotic disorder LLT
    9.1 10039628 Schizophrenia and other psychotic disorders HLGT
    9.1 10012256 Delusional disorders HLT
    9.1 10039621 Schizoaffective disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-004383-23 Sponsor Protocol Number: RISSCH4055 Start Date*: 2005-11-24
    Sponsor Name:Janssen Cilag Ltd
    Full Title: Pragmatic randomized trial of Risperdal Consta versus oral atypical antipsychotics in poorly adherent subjects with schizophrenia ina routine care setting. Protocol RISSCH4055; Phase IV (risperid...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003588-85 Sponsor Protocol Number: PSYCHIC Start Date*: 2022-01-11
    Sponsor Name:UCLouvain
    Full Title: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ?
    Medical condition: Schizophrenia, schizoaffective disorders, psychosis not otherwise specified, and dellusional disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020370-42 Sponsor Protocol Number: NN25310 Start Date*: 2011-01-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005138-21 Sponsor Protocol Number: TC-5619-23-CRD-003 Start Date*: 2012-04-03
    Sponsor Name:Targacept Inc.
    Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002960-85 Sponsor Protocol Number: NN20372 Start Date*: 2008-03-18
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on select atypical antipsychotics with prominent negative or disorganized thought sy...
    Medical condition: Schizophrenia - This study will be conducted to investigate whether or not administration of RO4917838 along with their current antipsychotic regimen to stable patients can lead to further improvem...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005435-87 Sponsor Protocol Number: FIBHGM-ECNC002-2012 Start Date*: 2013-02-14
    Sponsor Name:Fundación para la Investigación Biomédica Hospital Gregorio Marañón
    Full Title: EFFECT OF ADJUVANT TREATMENT WITH N - ACETYLCYSTEINE DURING 48 WEEKS ON THE LOSS OF GREY SUBSTANCE AND OXIDATIVE METABOLISM IN PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES: BLIND, PLACEBO-CONTROLLE...
    Medical condition: PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10061920 Psychotic disorder PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002147-27 Sponsor Protocol Number: Start Date*: 2005-05-26
    Sponsor Name:Department of General Psychiatry
    Full Title: Influence of treatment of olanzapine and ziprasidone on transcapillary glucose transport in human skeletal muscle
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004489-41 Sponsor Protocol Number: MRZ 90001-0716/1 Start Date*: 2008-02-21
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, single-arm, multi-center, open-label study to investigate the potential to reduce concomitant antipsychotics use in subjects with moderate dementia of Alzheimer’s type [DAT] treated wi...
    Medical condition: Dementia of Alzheimer’s Type [DAT] in subjects with Mini Mental State Examination [MMSE] score 10-19 and Global Deterioration Scale [GDS] score 3-5 and antipsychotics medication during the last 3 m...
    Disease: Version SOC Term Classification Code Term Level
    10.1 10012271 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020467-21 Sponsor Protocol Number: WN25309 Start Date*: 2010-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio en fase III multicéntrico aleatorizado, de 24 semanas, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes estables c...
    Medical condition: Tratamiento de los síntomas negativos en pacientes con esquizofrenia tratados con antipsicóticos Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001217-42 Sponsor Protocol Number: CN138-489 Start Date*: 2007-09-20
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome
    Medical condition: Subjects with schizophrenia who developed metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) GR (Prematurely Ended) CZ (Completed) ES (Completed) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000285-28 Sponsor Protocol Number: 1346.9 Start Date*: 2016-07-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patient...
    Medical condition: Patients with schizophrenia on stable antispychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039634 Schizophrenia residual LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020696-23 Sponsor Protocol Number: NN25307 Start Date*: 2011-03-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012003-26 Sponsor Protocol Number: RIS-NAP-4022 Start Date*: 2010-04-13
    Sponsor Name:Janssen-Cilag International, NV
    Full Title: Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
    Medical condition: Long-term safety data in children and adolescents will be collected from a population of patients with a diagnosis of schizophrenia, bipolar mania, autistic disorder or conduct and other disruptive...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    12.1 10026753 Manic and bipolar mood disorders and disturbances HLGT
    12.1 10003805 Autism LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020470-42 Sponsor Protocol Number: WN25308 Start Date*: 2011-01-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
    Medical condition: Treatment of negative symptoms for patients with schizophrenia treated with antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002055-15 Sponsor Protocol Number: J81J1100168007 Start Date*: 2014-01-28
    Sponsor Name:UNIVERSITY OF SASSARI
    Full Title: RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER P...
    Medical condition: BIPOLAR I MOOD DISORDERS
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020616-11 Sponsor Protocol Number: WN25306 Start Date*: 2011-03-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) SK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004891-10 Sponsor Protocol Number: Vocational Rehabilitation Start Date*: 2007-04-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Future strategies for vocational rehabilitation schizophrenia
    Medical condition: The social implications and long-term consequences of mental disorders regarding sick days at work, unemployment rates and early retirement are considerable. This trial is being conducted to unders...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:25:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA